Alkermes plc. Operating Lease, Expense
Alkermes plc. (ALKS) reported Operating Lease, Expense of $2.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-07-28
- Alkermes plc. operating lease, expense for the quarter ending 2026-06-30 was $2.20M, a 15.79% increase year-over-year.
- Alkermes plc. operating lease, expense for the quarter ending 2026-03-31 was $2.20M, a 22.22% increase year-over-year.
- Alkermes plc. operating lease, expense for the quarter ending 2025-12-31 was $1.90M, a 5.56% increase year-over-year.
- Alkermes plc. operating lease, expense for the quarter ending 2025-09-30 was $1.90M, a 5.56% increase year-over-year.
- Alkermes plc. operating lease, expense for fiscal 2025 was $7.50M, a 4.17% increase from fiscal 2024.
- Alkermes plc. operating lease, expense for fiscal 2024 was $7.20M, a 29.41% decline from fiscal 2023.
- Alkermes plc. operating lease, expense for fiscal 2023 was $10.20M, a 4.67% decline from fiscal 2022.
- Alkermes plc. operating lease, expense for fiscal 2022 was $10.70M, a 5.31% decline from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 3 month as first filed | Operating Lease, Expense 6 month | Operating Lease, Expense 6 month as first filed | Operating Lease, Expense 9 month | Operating Lease, Expense 9 month as first filed | Operating Lease, Expense 12 month | Operating Lease, Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.20M 10-Q · filed 2026-07-28 | $4.40M 10-Q · filed 2026-07-28 | $6.30M derived: sum of 3 quarters · filed 2026-07-28 | $8.20M derived: sum of 4 quarters · filed 2026-07-28 | ||||
| 2026-03-31 | $2.20M 10-Q · filed 2026-05-05 | $4.10M derived: sum of 2 quarters · filed 2026-05-05 | $6.00M derived: sum of 3 quarters · filed 2026-05-05 | $7.90M derived: sum of 4 quarters · filed 2026-07-28 | ||||
| 2025-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.80M derived: sum of 2 quarters · filed 2026-02-25 | $5.70M derived: sum of 3 quarters · filed 2026-07-28 | $7.50M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | $1.90M 10-Q · filed 2025-10-28 | $3.80M derived: sum of 2 quarters · filed 2026-07-28 | $5.60M 10-Q · filed 2025-10-28 | $7.40M derived: sum of 4 quarters · filed 2026-07-28 | ||||
| 2025-06-30 | $1.90M 10-Q · filed 2026-07-28 | $3.70M 10-Q · filed 2026-07-28 | $5.50M derived: sum of 3 quarters · filed 2026-07-28 | $7.30M derived: sum of 4 quarters · filed 2026-07-28 | ||||
| 2025-03-31 | $1.80M 10-Q · filed 2026-05-05 | $3.60M derived: sum of 2 quarters · filed 2026-05-05 | $5.40M derived: sum of 3 quarters · filed 2026-05-05 | $7.20M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.60M derived: sum of 2 quarters · filed 2026-02-25 | $5.40M derived: sum of 3 quarters · filed 2026-02-25 | $7.20M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $1.80M 10-Q · filed 2025-10-28 | $3.60M derived: sum of 2 quarters · filed 2025-10-28 | $5.40M 10-Q · filed 2025-10-28 | $7.20M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | $1.80M 10-Q · filed 2025-07-29 | $3.60M 10-Q · filed 2025-07-29 | $5.40M derived: sum of 3 quarters · filed 2026-02-25 | $8.20M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | $1.80M 10-Q · filed 2025-05-01 | $3.60M derived: sum of 2 quarters · filed 2026-02-25 | $6.40M derived: sum of 3 quarters · filed 2026-02-25 | $9.20M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $4.60M derived: sum of 2 quarters · filed 2026-02-25 | $7.40M derived: sum of 3 quarters · filed 2026-02-25 | $10.20M 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | $2.80M 10-Q · filed 2024-10-24 | $4.20M 10-Q · filed 2023-10-25 | $5.60M derived: sum of 2 quarters · filed 2024-10-24 | $8.40M 10-Q · filed 2024-10-24 | $12.70M 10-Q · filed 2023-10-25 | $6.60M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-06-30 | $2.80M 10-Q · filed 2024-07-24 | $4.20M 10-Q · filed 2023-07-26 | $5.60M 10-Q · filed 2024-07-24 | $8.50M 10-Q · filed 2023-07-26 | $3.80M derived: sum of 3 quarters · filed 2025-02-12 | $7.90M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-03-31 | $2.80M 10-Q · filed 2024-05-01 | $4.30M 10-Q · filed 2023-04-26 | $1.00M derived: sum of 2 quarters · filed 2025-02-12 | $5.10M derived: sum of 3 quarters · filed 2025-02-12 | $9.30M derived: sum of 4 quarters · filed 2025-02-12 | |||
| 2022-12-31 | -$1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $2.30M derived: sum of 2 quarters · filed 2025-02-12 | $6.50M derived: sum of 3 quarters · filed 2025-02-12 | $10.70M 10-K · filed 2025-02-12 | $16.60M 10-K · filed 2023-02-16 | |||
| 2022-09-30 | $4.10M 10-Q · filed 2023-10-25 | $8.30M derived: sum of 2 quarters · filed 2023-10-25 | $12.50M 10-Q · filed 2023-10-25 | $10.80M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-06-30 | $4.20M 10-Q · filed 2023-07-26 | $8.30M 10-Q · filed 2023-07-26 | $6.70M derived: sum of 3 quarters · filed 2024-02-21 | $11.00M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-03-31 | $4.10M 10-Q · filed 2023-04-26 | $2.50M derived: sum of 2 quarters · filed 2024-02-21 | $6.80M derived: sum of 3 quarters · filed 2024-02-21 | $11.20M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2021-12-31 | -$1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $2.70M derived: sum of 2 quarters · filed 2024-02-21 | $7.10M derived: sum of 3 quarters · filed 2024-02-21 | $11.30M 10-K · filed 2024-02-21 | $17.10M 10-K · filed 2022-02-16 | |||
| 2021-09-30 | $4.30M 10-Q · filed 2022-11-02 | $8.70M derived: sum of 2 quarters · filed 2022-11-02 | $12.90M 10-Q · filed 2022-11-02 | $16.90M derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2021-06-30 | $4.40M 10-Q · filed 2022-07-27 | $8.60M 10-Q · filed 2022-07-27 | $12.60M derived: sum of 3 quarters · filed 2023-02-16 | $17.30M derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2021-03-31 | $4.20M 10-Q · filed 2022-04-27 | $8.20M derived: sum of 2 quarters · filed 2023-02-16 | $12.90M derived: sum of 3 quarters · filed 2023-02-16 | $17.60M derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2020-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $8.70M derived: sum of 2 quarters · filed 2023-02-16 | $13.40M derived: sum of 3 quarters · filed 2023-02-16 | $17.30M 10-K · filed 2023-02-16 | $16.30M 10-K · filed 2021-02-11 | |||
| 2020-09-30 | $4.70M 10-Q · filed 2021-10-27 | $9.40M derived: sum of 2 quarters · filed 2021-10-27 | $13.30M 10-Q · filed 2021-10-27 | $15.10M derived: sum of 4 quarters · filed 2022-02-16 | ||||
| 2020-06-30 | $4.70M 10-Q · filed 2021-07-28 | $8.60M 10-Q · filed 2021-07-28 | $10.40M derived: sum of 3 quarters · filed 2022-02-16 | $12.50M derived: sum of 4 quarters · filed 2022-02-16 | ||||
| 2020-03-31 | $3.90M 10-Q · filed 2021-04-28 | $5.70M derived: sum of 2 quarters · filed 2022-02-16 | $7.80M derived: sum of 3 quarters · filed 2022-02-16 | $9.90M derived: sum of 4 quarters · filed 2022-02-16 | ||||
| 2019-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $3.90M derived: sum of 2 quarters · filed 2022-02-16 | $6.00M derived: sum of 3 quarters · filed 2022-02-16 | $8.10M 10-K · filed 2022-02-16 | ||||
| 2019-09-30 | $2.10M 10-Q · filed 2020-10-29 | $4.20M derived: sum of 2 quarters · filed 2020-10-29 | $6.30M 10-Q · filed 2020-10-29 | |||||
| 2019-06-30 | $2.10M 10-Q · filed 2020-07-29 | $4.20M 10-Q · filed 2020-07-29 | ||||||
| 2019-03-31 | $2.10M 10-Q · filed 2020-04-29 | |||||||
| 2018-12-31 | $10.80M 10-K · filed 2021-02-11 | |||||||
| 2017-12-31 | $9.40M 10-K · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |